Table of Contents Author Guidelines Submit a Manuscript
International Journal of Hypertension
Volume 2011 (2011), Article ID 284823, 11 pages
http://dx.doi.org/10.4061/2011/284823
Clinical Study

Differential Effects in Cardiovascular Markers between High-Dose Angiotensin II Receptor Blocker Monotherapy and Combination Therapy of ARB with Calcium Channel Blocker in Hypertension (DEAR Trial)

1Department of Endocrinology, Metabolism, and Nephrology, Keio University School of Medicine, Tokyo 160-8582, Japan
2Department of Endocrinology and Anti-Aging Medicine and Internal Medicine, Keio University School of Medicine, Tokyo 160-8582, Japan

Received 12 March 2011; Accepted 6 April 2011

Academic Editor: Samy I. McFarlane

Copyright © 2011 Kenichiro Kinouchi et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. S. Laurent, P. Boutouyrie, R. Asmar et al., “Aortic stiffness is an independent predictor of all-cause and cardiovascular mortality in hypertensive patients,” Hypertension, vol. 37, no. 5, pp. 1236–1241, 2001. View at Google Scholar · View at Scopus
  2. M. E. Safar, “Systolic blood pressure, pulse pressure and arterial stiffness as cardiovascular risk factors,” Current Opinion in Nephrology and Hypertension, vol. 10, no. 2, pp. 257–261, 2001. View at Publisher · View at Google Scholar · View at Scopus
  3. B. Williams, P. Lacy, S. Thom et al., “Differential impact of blood pressure-lowering drugs on central aortic pressure and clinical outcomes: principal results of the Conduit Artery Function Evaluation (CAFE) study,” Circulation, vol. 113, no. 9, pp. 1213–1225, 2006. View at Google Scholar
  4. A. Ichihara, N. Yamashita, T. Takemitsu et al., “Cardio-ankle vascular index and ankle pulse wave velocity as a marker of arterial fibrosis in kidney failure treated by hemodialysis,” American Journal of Kidney Diseases, vol. 52, no. 5, pp. 947–955, 2008. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  5. A. Mahmud and J. Feely, “Effect of angiotensin II receptor blockade on arterial stiffness: beyond blood pressure reduction,” American Journal of Hypertension, vol. 15, no. 12, pp. 1092–1095, 2002. View at Publisher · View at Google Scholar · View at Scopus
  6. K. Bokuda, A. Ichihara, M. Sakoda, A. Mito, K. Kinouchi, and H. Itoh, “Blood pressure-independent effect of candesartan on cardio-ankle vascular index in hypertensive patients with metabolic syndrome,” Vascular Health and Risk Management, vol. 6, pp. 571–578, 2010. View at Google Scholar
  7. K. Kinouchi, A. Ichihara, M. Sakoda, A. Kurauchi-Mito, and H. Itoh, “Safety and benefits of a tablet combining losartan and hydrochlorothiazide in Japanese diabetic patients with hypertension,” Hypertension Research, vol. 32, no. 12, pp. 1143–1147, 2009. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  8. K. Kinouchi, A. Ichihara, M. Sakoda, A. Kurauchi-Mito, K. Murohashi-Bokuda, and H. Itoh, “Effects of telmisartan on arterial stiffness assessed by the cardio-ankle vascular index in hypertensive patients,” Kidney and Blood Pressure Research, vol. 33, no. 4, pp. 304–312, 2010. View at Publisher · View at Google Scholar · View at PubMed
  9. Y. Miyashita, A. Saiki, K. Endo et al., “Effects of olmesartan, an angiotensin II receptor blocker, and amlodipine, a calcium channel blocker, on Cardio-Ankle Vascular Index (CAVI) in type 2 diabetic patients with hypertension,” Journal of Atherosclerosis and Thrombosis, vol. 16, no. 5, pp. 621–626, 2009. View at Google Scholar · View at Scopus
  10. T. Miyoshi, M. Doi, S. Hirohata et al., “Olmesartan reduces arterial stiffness and serum adipocyte fatty acid-binding protein in hypertensive patients,” Heart and Vessels. In press. View at Publisher · View at Google Scholar · View at PubMed
  11. A. Ichihara, Y. Kaneshiro, T. Takemitsu, and M. Sakoda, “Effects of amlodipine and valsartan on vascular damage and ambulatory blood pressure in untreated hypertensive patients,” Journal of Human Hypertension, vol. 20, no. 10, pp. 787–794, 2006. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  12. J. M. Li, M. Iwai, T. X. Cui et al., “Effect of azelnidipine on angiotensin II-mediated growth-promoting signaling in vascular smooth muscle cells,” Molecular Pharmacology, vol. 67, no. 5, pp. 1666–1673, 2005. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  13. T. Jinno, M. Iwai, Z. Li et al., “Calcium channel blocker azelnidipine enhances vascular protective effects of AT1 receptor blocker olmesartan,” Hypertension, vol. 43, no. 2, pp. 263–269, 2004. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  14. S. Inaba, M. Iwai, Y. Tomono et al., “Prevention of vascular injury by combination of an AT1 receptor blocker, olmesartan, with various calcium antagonists,” American Journal of Hypertension, vol. 22, no. 2, pp. 145–150, 2009. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  15. Y. Matsui, K. Eguchi, M. F. O'Rourke et al., “Differential effects between a calcium channel blocker and a diuretic when used in combination with angiotensin II receptor blocker on central aortic pressure in hypertensive patients,” Hypertension, vol. 54, no. 4, pp. 716–723, 2009. View at Publisher · View at Google Scholar · View at PubMed
  16. J. Suzuki, M. Iwai, Z. Li et al., “Effect of combination of calcium antagonist, azelnidipine, and AT1 receptor blocker, olmesartan, on atherosclerosis in apolipoprotein E-deficient mice,” Journal of Hypertension, vol. 23, no. 7, pp. 1383–1389, 2005. View at Google Scholar · View at Scopus
  17. T. Tada, J. Nawata, H. Wang et al., “Enhanced pulsatile pressure accelerates vascular smooth muscle migration: implications for atherogenesis of hypertension,” Cardiovascular Research, vol. 80, no. 3, pp. 346–353, 2008. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  18. X. W. Cheng, K. Okumura, M. Kuzuya et al., “Mechanism of diastolic stiffening of the failing myocardium and its prevention by angiotensin receptor and calcium channel blockers,” Journal of Cardiovascular Pharmacology, vol. 54, no. 1, pp. 47–56, 2009. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  19. S. Kim-Mitsuyama, Y. Izumi, Y. Izumiya, K. Yoshida, M. Yoshiyama, and H. Iwao, “Additive beneficial effects of the combination of a calcium channel blocker and an angiotensin blocker on a hypertensive rat-heart failure model,” Hypertension Research, vol. 27, no. 10, pp. 771–779, 2004. View at Publisher · View at Google Scholar · View at Scopus
  20. H. Lu, M. Kanazawa, A. Ishida et al., “Combination of chronic exercise and antihypertensive therapy enhances renoprotective effects in rats with renal ablation,” American Journal of Hypertension, vol. 22, no. 10, pp. 1101–1106, 2009. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  21. C. Tanifuji, Y. Suzuki, W. M. Geot, S. Horikoshi, H. Takahashi, and Y. Tomino, “Beneficial effects of combination therapy with olmesartan and azelnidipine in murine polycystic kidneys,” Kidney and Blood Pressure Research, vol. 32, no. 4, pp. 239–249, 2009. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  22. T. Willum-Hansen, J. A. Staessen, C. Torp-Pedersen et al., “Prognostic value of aortic pulse wave velocity as index of arterial stiffness in the general population,” Circulation, vol. 113, no. 5, pp. 664–670, 2006. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  23. A. Dawson, J. I. Davies, A. D. Morris, and A. D. Struthers, “B-type natriuretic peptide is associated with both augmentation index and left ventricular mass in diabetic patients without heart failure,” American Journal of Hypertension, vol. 18, no. 12, pp. 1586–1591, 2005. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  24. S. Sakuragi, T. Maruo, M. Taniguchi et al., “Radial augmentation index associated with increase in B-type natriuretic peptide in patients with hypertension,” International Journal of Cardiology, vol. 130, no. 3, pp. 414–419, 2008. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  25. R. Asmar, P. Gosse, J. Topouchian, G. N'tela, A. Dudley, and G. L. Shepherd, “Effects of telmisartan on arterial stiffness in type 2 diabetes patients with esssential hypertension,” Journal of the Renin-Angiotensin-Aldosterone System, vol. 3, no. 3, pp. 176–180, 2002. View at Google Scholar · View at Scopus
  26. M. Doi, T. Miyoshi, S. Hirohata et al., “Combination therapy of calcium channel blocker and angiotensin II receptor blocker reduces augmentation index in hypertensive patients,” American Journal of the Medical Sciences, vol. 339, no. 5, pp. 433–439, 2010. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  27. T. Ishimitsu, A. Numabe, T. Masuda et al., “Angiotensin-II receptor antagonist combined with calcium channel blocker or diuretic for essential hypertension,” Hypertension Research, vol. 32, no. 11, pp. 962–968, 2009. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  28. T. Nada, M. Nomura, K. Koshiba, T. Kawano, J. Mikawa, and S. Ito, “Clinical study with azelnidipine in patients with essential hypertension. Antiarteriosclerotic and cardiac hypertrophy-inhibitory effects and influence on autonomic nervous activity,” Arzneimittelforschung, vol. 57, no. 11, pp. 698–704, 2007. View at Google Scholar
  29. C. Ohmura, H. Watada, T. Shimizu et al., “Calcium channel blocker, azelnidipine, reduces lipid hydroperoxides in patients with type 2 diabetes independent of blood pressure,” Endocrine Journal, vol. 54, no. 5, pp. 805–811, 2007. View at Publisher · View at Google Scholar · View at Scopus
  30. T. Ogihara, T. Saruta, K. Shimada, and K. Kuramoto, “A randomized, double-blind, four-arm parallel-group study of the efficacy and safety of azelnidipine and olmesartan medoxomil combination therapy compared with each monotherapy in Japanese patients with essential hypertension: the REZALT study,” Hypertension Research, vol. 32, no. 12, pp. 1148–1154, 2009. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus